AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 89 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 1.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $16,299 | -40.8% | 36,179 | -40.8% | 0.00% | – |
| Q4 2022 | $27,509 | -16.6% | 61,143 | -6.2% | 0.00% | – |
| Q2 2022 | $33,000 | -62.9% | 65,195 | +482.5% | 0.00% | – |
| Q3 2021 | $89,000 | -47.0% | 11,192 | -47.5% | 0.00% | – |
| Q4 2020 | $168,000 | +110.0% | 21,322 | +90.1% | 0.00% | – |
| Q3 2020 | $80,000 | +14.3% | 11,218 | -25.3% | 0.00% | – |
| Q1 2020 | $70,000 | -41.7% | 15,022 | -3.9% | 0.00% | – |
| Q3 2019 | $120,000 | -27.7% | 15,627 | -35.3% | 0.00% | – |
| Q2 2019 | $166,000 | -74.6% | 24,140 | -85.8% | 0.00% | – |
| Q2 2017 | $653,000 | – | 170,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 279,678 | $2,587,000 | 10.00% |
| Aisling Capital Management LP | 1,691,151 | $15,643,000 | 5.97% |
| Samsara BioCapital, LLC | 967,500 | $8,949,000 | 2.88% |
| Bain Capital Life Sciences Investors, LLC | 2,700,000 | $24,975,000 | 2.62% |
| Soleus Capital Management, L.P. | 369,852 | $3,421,000 | 1.95% |
| Nantahala Capital Management | 3,204,830 | $29,645,000 | 0.89% |
| Lion Point Capital, LP | 300,000 | $2,775,000 | 0.67% |
| Abingworth LLP | 240,500 | $2,221,000 | 0.62% |
| Sio Capital Management, LLC | 211,104 | $1,953,000 | 0.57% |
| Orbimed Advisors | 4,015,524 | $37,144,000 | 0.52% |